The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TAKHZYRO (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
TAKHZYRO
Date registered
Evaluation commenced
Decision date
Approval time
221 (255 working days)
Active ingredients
lanadelumab
Registration type
EOI
Indication
TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (C1-esterase-inhibitor deficiency or dysfunction) in patients aged 2 years and older.